Table 2.
Ongoing clinical trials of targeted therapies for endometrial cancer (ClinicalTrials.gov)
| Inhibitor | Molecular target | Phase | Monotherapy/combination therapy | Trial identifier |
|---|---|---|---|---|
| Temsirolimus | mTOR | II | Combination | NCT01010126 |
| Temsirolimus | mTOR | II | Combination | NCT00977574 |
| Temsirolimus | mTOR | I | Combination | NCT00982631 |
| Ridaforolimus | mTOR | I | Combination | NCT01256268 |
| Everolimus | mTOR | I | Combination | NCT00703807 |
| MK2206 | AKT | II | Monotherapy | NCT01307631 |
| BKM120 | PI3K | II | Monotherapy | NCT01397877 |
| XL147 | PI3K | II | Monotherapy | NCT01013324 |
| XL147 | PI3K | I | Combination | NCT00756847 |
| GDC-0980 | PI3K | II | Monotherapy | NCT01455493 |
| BKM120 | Pan-PI3K | II | Monotherapy | NCT01289041 |
| DS-7423 | PI3K/mTOR | I | Monotherapy | NCT01364844 |
| BEZ235 | PI3K/mTOR | II | Monotherapy | NCT01290406 |
| PF-04691502/PF-05212384 | PI3K-mTOR/PI3K-mTOR | II | Combination | NCT01420081 |
| XL147/MSC1936369B | PI3K/MEK | I | Combination | NCT01357330 |
| GSK1120212/GSK2110183 | MEK/AKT | I | Combination | NCT01476137 |
| MSC1936369B/SAR245409 | MEK/PI3K-mTOR | I | Combination | NCT01390818 |
| FP-1039 | FGF | II | Monotherapy | NCT01244438 |
| Trastuzumab | HER-2 | II | Combination | NCT01367002 |
| ARRY-380 | HER-2 | I | Monotherapy | NCT00650572 |
| BIBF 1120 | VEGFR/FGFR/PDGFR | II | Monotherapy | NCT01225887 |
| TKI258 | RTKs | II | Monotherapy | NCT01379534 |
| Sunitinib or temsirolimus | RTKs/mTOR | II | Monotherapy | NCT01396408 |
| GSK2636771 | PTEN-deficiency | I/IIa | Monotherapy | NCT01458067 |
| ARRY-382 | CSF-1 receptor | I | Monotherapy | NCT01316822 |
| RO4929097/temsirolimus | Gamma-secretase/mTOR | I | Combination | NCT01198184 |
| Olaparib | PARP | I | Combination | NCT01237067 |